TQB 2252
Alternative Names: Penpulimab/TQB2223 - Chia Tai Tianqing Pharmaceutical; TQB-2252; TQB2223/Penpulimab - Chia Tai Tianqing PharmaceuticalLatest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 Oct 2024 Preclinical trials in Solid tumours in China (IV) (NCT06649656)
- 21 Oct 2024 Chia Tai Tianqing Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease) in China (NCT06649656)